NCT03029650View on ClinicalTrials.gov

Scopolamine Patch Pharmacokinetics in Healthy Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

March 31, 2018

Conditions
Healthy
Interventions
DRUG

Transderm Scop®

TDDS dosage is 1.5 mg/72 hrs

DRUG

Intravenous scopolamine hydrobromide

0.4 mg via intravenous injection

Trial Locations (1)

52242

University of Iowa, Iowa City

All Listed Sponsors
collaborator

University of Minnesota

OTHER

lead

University of Iowa

OTHER

NCT03029650 - Scopolamine Patch Pharmacokinetics in Healthy Adults | Biotech Hunter | Biotech Hunter